Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.40 |
| ▸ | BAZ2B | Q9UIF8 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 2/20 | 0.39 |
| ▸ | MEN1 | O00255 | 3/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.38 |
| ▸ | MAPT | P10636 | 4/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.38 |
| ▸ | HPGD | P15428 | 3/20 | 0.38 |
| ▸ | CASP1 | P29466 | 3/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.38 |
| ▸ | CASP7 | P55210 | 2/20 | 0.38 |
| ▸ | NPC1 | O15118 | 2/20 | 0.38 |
| ▸ | RAB9A | P51151 | 2/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.37 |
| ▸ | PKM | P14618 | 1/20 | 0.37 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22591293 | 0.79 | BAZ2B (0.43) | ALDH1A1BAZ2BHTTL3MBTL1MAPT | |
| SCHEMBL17052373 | 0.78 | KDM4E (0.42) | ALDH1A1HTTMEN1KMT2AGAA | |
| SCHEMBL19995853 | 0.76 | ALDH1A1 (0.44) | ALDH1A1BAZ2BHTTMEN1KMT2A | |
| SCHEMBL30908352 | 0.75 | KDM4E (0.52) | ALDH1A1MEN1KMT2AL3MBTL1KDM4E | |
| SCHEMBL13254783 | 0.75 | HDAC1 (0.45) | BAZ2BHTTMEN1KMT2AGAA | |
| SCHEMBL8790522 | 0.75 | KDM4E (0.54) | ALDH1A1BAZ2BHTTMEN1KMT2A | |
| SCHEMBL3827983 | 0.75 | PGK1 (0.48) | ALDH1A1BAZ2BHTTMEN1KMT2A | |
| SCHEMBL22827947 | 0.75 | NLRP3 (0.53) | ALDH1A1BAZ2BMAPTSMN1; SMN2HPGD | |
| SCHEMBL433839 | 0.75 | CA1 (0.45) | ALDH1A1BAZ2BHTTKDM4EMAPT | |
| SCHEMBL30951184 | 0.75 | PGK1 (0.48) | ALDH1A1BAZ2BHTTMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2595966-B1 | SYNTHESIS OF CYCLOPENTAQUINAZOLINES | BTG INT LTD (GB) | 2020-10-28 | — | — | EP | disclosed |
| US-8809526-B2 | Synthesis of cyclopentaquinazolines | ONYX PHARMACEUTICALS, INC. (US) | 2014-08-19 | — | — | US | disclosed |
| EP-2213664-B1 | PROCESS FOR THE PREPARATION OF CYCLOPENTA[G]QUINAZOLINE DERIVATIVES | BTG INT LTD (GB) | 2014-04-30 | — | — | EP | disclosed |
| US-20130211082-A1 | Synthesis of Cyclopentaquinazolines | ONYX PHARMACEUTICALS, INC. (US) | 2013-08-15 | — | — | US | disclosed |
| WO-2012011939-A2 | SYNTHESIS OF CYCLOPENTAQUINAZOLINES | ONYX PHARMACEUTICALS, INC. (US) | 2012-01-26 | — | — | WO | disclosed |
| EP-1421069-B1 | PROCESS FOR THE PREPARATION OF CYCLOPENTA[G]QUINAZOLINE DERIVATIVES | BTG INT LTD (GB) | 2011-08-10 | — | — | EP | disclosed |
| EP-2213664-A1 | PROCESS FOR THE PREPARATION OF CYCLOPENTA[G]QUINAZOLINE DERIVATIVES | BTG International Limited (GB) | 2010-08-04 | — | — | EP | disclosed |
| US-7250511-B2 | Process for the preparation of cyclopenta[g]quinazoline derivatives | BTG INTERNATIONAL LIMITED (GB) | 2007-07-31 | — | — | US | disclosed |
| EP-0758328-B1 | ANTI-CANCER COMPOUNDS CONTAINING CYCLOPENTAQUINAZOLINE RING | BTG INT LTD (GB) | 2003-07-16 | — | — | EP | disclosed |
| US-5789417-A | ANTICARCINOGENIC AGENTS | ZENECA LIMITED (GB) | 1998-08-04 | — | — | US | disclosed |
| US-5747499-A | CYCLOPENTAQUINAZOLINE COMPOUNDS CYCLOPENTAQUINAZOLINE COMPOUNDS | BRITISH TECHNOLOGY GROUP LIMITED (GB) | 1998-05-05 | — | — | US | disclosed |
| EP-0667864-B1 | TRICYCLIC COMPOUNDS WITH PHARMACEUTICAL ACTIVITY | ZENECA LTD (GB) | 1997-09-24 | — | — | EP | disclosed |
| EP-0758328-A1 | ANTI-CANCER COMPOUNDS CONTAINING CYCLOPENTAQUINAZOLINE RING | BTG INTERNATIONAL LIMITED (GB) | 1997-02-19 | — | — | EP | disclosed |
| US-5580870-A | ANTICARCINOGENIC AGENTS | ZENECA LIMITED (GB) | 1996-12-03 | — | — | US | disclosed |
| EP-0602851-B1 | Quinazoline derivatives | ZENECA LTD (GB) | 1996-10-09 | — | — | EP | disclosed |
| WO-1995030673-A1 | ANTI-CANCER COMPOUNDS CONTAINING CYCLOPENTAQUINAZOLINE RING | BRITISH TECHNOLOGY GROUP LIMITED (GB) | 1995-11-16 | — | — | WO | disclosed |
| EP-0667864-A1 | TRICYCLIC COMPOUNDS WITH PHARMACEUTICAL ACTIVITY. | ZENECA LTD (GB) | 1995-08-23 | — | — | EP | disclosed |
| WO-1995009158-A1 | TRICYCLIC DERIVATIVES | ZENECA LIMITED (GB) | 1995-04-06 | — | — | WO | disclosed |
| EP-0602851-A1 | Quinazoline derivatives | ZENECA LIMITED (GB) | 1994-06-22 | — | — | EP | disclosed |
| WO-1994011354-A1 | TRICYCLIC COMPOUNDS WITH PHARMACEUTICAL ACTIVITY | ZENECA LIMITED (GB) | 1994-05-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130211082-A1 | Synthesis of Cyclopentaquinazolines | GLUL, QPCT, ASNS | ALDH1A1 1802/4885BAZ2B 3446/4885HTT 2883/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.